Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma. NICE technology appraisal guidance 1145
National Institute for Health and Care Excellence (NICE)
Record ID 32018015233
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1145
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/ta1145
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Adult
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Immune Checkpoint Inhibitors
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.